• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

掌腱膜挛缩症的流行病学及接受选择性筋膜切除术的患者

Epidemiology of Dupuytren disease and Patients Undergoing Selective Fasciectomy.

作者信息

Alencar Fernando Henrique Uchôa de, Perini Jamila Alessandra, Monteiro Anderson Vieira, Duarte Maria Eugenia Leite, Motta Geraldo da Rocha, Guimarães João Antônio Matheus

机构信息

Centro de Cirurgia da Mão, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil.

Divisão de Pesquisa, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil.

出版信息

Rev Bras Ortop (Sao Paulo). 2021 Aug;56(4):478-484. doi: 10.1055/s-0040-1721839. Epub 2021 Mar 22.

DOI:10.1055/s-0040-1721839
PMID:34483392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8405273/
Abstract

To describe the epidemiological and clinical profile of patients with Dupuytren disease treated by selective fasciectomy and the factors associated with the severity of the disease.  Retrospective descriptive observational study involving 247 patients with Dupuytren disease, from 2013 to 2019. Multivariate logistic regression was performed for data analysis.  Most patients were male (83.8%), self-declared white (65.2%), alcoholics (59.6%) and 49% were smokers, with a mean age of 66 ± 9 years old, with 77.2% presenting symptoms of the disease after the age of 51 years old. Approximately 51.9, 29.6 and 17.3%, respectively, had arterial hypertension, diabetes mellitus and dyslipidemia comorbidities. Bilateral involvement of the hands was observed in 73.3% of the patients. The rate of intra- and post-selective fasciectomy complications was of 0.6 and 24.3%, respectively, with 5.2% of the patients needing reintervention after 1 year of follow-up. After multivariate analysis, males were associated with bilateral involvement of the hands (odds ratio [OR] = 2.10; 95% confidence interval [CI]: 1.03-4.31) and with a greater number of affected rays (OR = 3.41; 95% CI: 1.66-7.03). Dyslipidemia was associated with reintervention (OR = 5.7; 95% CI = 1.03-31.4) and bilaterality with a higher number of complications (35.7 versus 19.7%).  A low rate of reintervention and operative complications was observed in patients with Dupuytren disease treated by selective fasciectomy. Male gender was associated with severe disease (bilaterality and more than two affected rays), and dyslipidemia with reintervention.

摘要

描述接受选择性筋膜切除术治疗的掌腱膜挛缩症患者的流行病学和临床特征,以及与疾病严重程度相关的因素。 2013年至2019年,对247例掌腱膜挛缩症患者进行回顾性描述性观察研究。采用多因素逻辑回归进行数据分析。 大多数患者为男性(83.8%),自称白人(65.2%),酗酒者(59.6%),49%为吸烟者,平均年龄66±9岁,77.2%在51岁后出现疾病症状。分别约有51.9%、29.6%和17.3%的患者合并动脉高血压、糖尿病和血脂异常。73.3%的患者双手受累。选择性筋膜切除术中及术后并发症发生率分别为0.6%和24.3%,5.2%的患者在随访1年后需要再次干预。多因素分析后,男性与双手受累(优势比[OR]=2.10;95%置信区间[CI]:1.03-4.31)以及更多受累指(OR=3.41;95%CI:1.66-7.03)相关。血脂异常与再次干预相关(OR=5.7;95%CI=1.03-31.4),双手受累且并发症较多(35.7%对19.7%)。 接受选择性筋膜切除术治疗的掌腱膜挛缩症患者再次干预和手术并发症发生率较低。男性与严重疾病(双手受累和两个以上受累指)相关,血脂异常与再次干预相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/ade7609a1c1a/10-1055-s-0040-1721839-i2000110pt-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/3931054491eb/10-1055-s-0040-1721839-i2000110en-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/de9cb0491ddc/10-1055-s-0040-1721839-i2000110en-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/428ca8a69fc1/10-1055-s-0040-1721839-i2000110en-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/69995ec91698/10-1055-s-0040-1721839-i2000110pt-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/9d6b0ed581ec/10-1055-s-0040-1721839-i2000110pt-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/ade7609a1c1a/10-1055-s-0040-1721839-i2000110pt-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/3931054491eb/10-1055-s-0040-1721839-i2000110en-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/de9cb0491ddc/10-1055-s-0040-1721839-i2000110en-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/428ca8a69fc1/10-1055-s-0040-1721839-i2000110en-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/69995ec91698/10-1055-s-0040-1721839-i2000110pt-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/9d6b0ed581ec/10-1055-s-0040-1721839-i2000110pt-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482e/8405273/ade7609a1c1a/10-1055-s-0040-1721839-i2000110pt-3.jpg

相似文献

1
Epidemiology of Dupuytren disease and Patients Undergoing Selective Fasciectomy.掌腱膜挛缩症的流行病学及接受选择性筋膜切除术的患者
Rev Bras Ortop (Sao Paulo). 2021 Aug;56(4):478-484. doi: 10.1055/s-0040-1721839. Epub 2021 Mar 22.
2
Outcomes and Direct Costs of Needle Aponeurotomy, Collagenase Injection, and Fasciectomy in the Treatment of Dupuytren Contracture.针刺腱膜切开术、胶原酶注射及筋膜切除术治疗掌腱膜挛缩症的疗效及直接成本
J Hand Surg Am. 2019 Nov;44(11):919-927. doi: 10.1016/j.jhsa.2019.07.017. Epub 2019 Sep 17.
3
Predictors of Outcomes Following Fasciectomy for Dupuytren's Disease in Diabetic and Non-Diabetic Patients.糖尿病患者和非糖尿病患者 Dupuytren 挛缩症筋膜切除术后的预后预测因素
J Hand Surg Asian Pac Vol. 2017 Sep;22(3):309-314. doi: 10.1142/S0218810417500356.
4
Dupuytren Disease Management Trends: A Survey of Hand Surgeons.掌腱膜挛缩症的治疗管理趋势:对手外科医生的调查。
Hand (N Y). 2020 Jan;15(1):97-102. doi: 10.1177/1558944718787281. Epub 2018 Jul 25.
5
Preliminary soft-tissue distraction versus checkrein ligament release after fasciectomy in the treatment of dupuytren proximal interphalangeal joint contractures.掌腱膜切开术后软组织牵张与韧带阻挡松解治疗近端指间关节挛缩
Plast Reconstr Surg. 2011 Nov;128(5):1107-1113. doi: 10.1097/PRS.0b013e31822b67c9.
6
Cost comparison of open fasciectomy versus percutaneous needle aponeurotomy for treatment of Dupuytren contracture.开放性筋膜切除术与经皮针状腱膜切开术治疗掌腱膜挛缩症的成本比较
Ann Plast Surg. 2013 Apr;70(4):454-6. doi: 10.1097/SAP.0b013e31827e531d.
7
The burden of productivity loss of U.S. commercially insured patients diagnosed with Dupuytren's disease undergoing collagenase versus fasciectomy treatment.美国商业保险患者因诊断为掌腱膜挛缩症而接受胶原酶与筋膜切除术治疗的生产力损失负担。
Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):127-136. doi: 10.1080/14737167.2020.1770085. Epub 2020 Jun 21.
8
Fasciectomy under local anaesthetic and adrenaline for Dupuytren's contracture in a community setting in the UK with a cost analysis.在英国社区环境下,于局麻加肾上腺素下行掌腱膜挛缩切除术:一项成本分析。
Bone Joint J. 2020 Oct;102-B(10):1354-1358. doi: 10.1302/0301-620X.102B10.BJJ-2019-1685.R2.
9
Characterization and outcomes of reinterventions in Food and Drug Administration-approved versus trial endovascular aneurysm repair devices.经食品和药物管理局批准的与试验性血管内动脉瘤修复装置的再干预特征和结果。
J Vasc Surg. 2018 Apr;67(4):1082-1090. doi: 10.1016/j.jvs.2017.08.058. Epub 2017 Oct 23.
10
Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy for Dupuytren's Contracture: 5-Year Results from a Randomized Clinical Trial.经皮腱膜切开术联合脂肪填充与局限性筋膜切除术治疗掌腱膜挛缩症的随机临床试验 5 年结果。
Plast Reconstr Surg. 2018 Dec;142(6):1523-1531. doi: 10.1097/PRS.0000000000004982.

本文引用的文献

1
Patient's satisfaction beyond hand function in Dupuytren's disease: analysis of 1106 patients.Dupuytren挛缩病患者手部功能之外的满意度:1106例患者分析
J Hand Surg Eur Vol. 2020 Mar;45(3):280-285. doi: 10.1177/1753193419890284. Epub 2019 Nov 28.
2
Outcomes and Direct Costs of Needle Aponeurotomy, Collagenase Injection, and Fasciectomy in the Treatment of Dupuytren Contracture.针刺腱膜切开术、胶原酶注射及筋膜切除术治疗掌腱膜挛缩症的疗效及直接成本
J Hand Surg Am. 2019 Nov;44(11):919-927. doi: 10.1016/j.jhsa.2019.07.017. Epub 2019 Sep 17.
3
Dupuytren contracture: comparative study between partial fasciectomy and percutaneous fasciectomy.
杜普伊特伦挛缩:部分筋膜切除术与经皮筋膜切除术的比较研究
Rev Bras Ortop. 2014 Jan 4;48(6):545-553. doi: 10.1016/j.rboe.2013.12.021. eCollection 2013 Nov-Dec.
4
Dorsal Dupuytren's disease: a systematic review of published cases and treatment options.背侧杜普伊特伦挛缩症:已发表病例及治疗选择的系统评价
J Hand Surg Eur Vol. 2019 Nov;44(9):963-971. doi: 10.1177/1753193419852171. Epub 2019 Jun 11.
5
Fasciectomy for Dupuytren Contracture.
Hand Clin. 2018 Aug;34(3):351-366. doi: 10.1016/j.hcl.2018.04.002.
6
Risk Factors, Disease Associations, and Dupuytren Diathesis.风险因素、疾病关联与掌腱膜挛缩素质
Hand Clin. 2018 Aug;34(3):307-314. doi: 10.1016/j.hcl.2018.03.002.
7
A Systematic Review and Meta-Analysis on the Strength and Consistency of the Associations between Dupuytren Disease and Diabetes Mellitus, Liver Disease, and Epilepsy.一项关于杜普伊特伦挛缩症与糖尿病、肝脏疾病和癫痫之间关联强度和一致性的系统评价和荟萃分析。
Plast Reconstr Surg. 2018 Mar;141(3):367e-379e. doi: 10.1097/PRS.0000000000004120.
8
Epidemiological analysis of patients with Dupuytren's disease.掌腱膜挛缩症患者的流行病学分析。
Rev Bras Ortop. 2017 Dec 14;53(1):10-14. doi: 10.1016/j.rboe.2017.12.003. eCollection 2018 Jan-Feb.
9
[Epidemiology of Dupuytren's disease].[掌腱膜挛缩症的流行病学]
Orthopade. 2017 Apr;46(4):298-302. doi: 10.1007/s00132-017-3384-8.
10
Meta-Analysis of Genome-Wide Association Studies and Network Analysis-Based Integration with Gene Expression Data Identify New Suggestive Loci and Unravel a Wnt-Centric Network Associated with Dupuytren's Disease.全基因组关联研究的荟萃分析以及基于网络分析与基因表达数据的整合,鉴定出新的潜在基因座并揭示与掌腱膜挛缩症相关的以Wnt为中心的网络。
PLoS One. 2016 Jul 28;11(7):e0158101. doi: 10.1371/journal.pone.0158101. eCollection 2016.